By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Insight Genetics today announced an exclusive worldwide licensing agreement with St. Jude Children's Hospital to develop a diagnostic test directed at the anaplastic lymphoma kinase, or ALK, gene to better monitor cancer patients and enable physicians to prescribe more effective treatments.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.